SMMT
Summit Therapeutics Inc.Company Information
- Company Name
- Summit Therapeutics Inc.
- CIK
- CIK0001599298
- Category
- Large accelerated filer
- Ticker: Exchange
- SMMT: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- SMMT
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-06-12
- Last sale
- —
- Shares purchased (TTM)
- 8,466,977
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 132,529,164
- Shares outstanding
- 778,184,568
- Ownership
- 17.03%
Earnings Market Reaction
- Filing date
- 2026-07-23
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 419 | 107 | 225 | 239 | 298 | 212 | 105 | 94 | 28 | 61 | 71 | 24 | ||||||
| Restricted Cash Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accounts Receivable Net Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Short Term Investments | 271 | 492 | 488 | 0 | 0 | 150 | 307 | 393 | 297 | 95 | 115 | 175 | ||||||
| Prepaid Expense And Other Assets Current | 30 | 18 | 7 | 8 | 11 | 9 | 11 | 2 | 2 | 5 | 3 | - | ||||||
| Prepaid Expense Current | - | - | - | - | - | - | - | - | - | - | 2 | 5 | ||||||
| Assets Current | 721 | 617 | 720 | 246 | 309 | 371 | 424 | 490 | 329 | 163 | 190 | 205 | ||||||
| Other Assets Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Property Plant And Equipment Net | 2 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 19 | 19 | 21 | 5 | 6 | 6 | 7 | 8 | 9 | 9 | 6 | 6 | ||||||
| Goodwill | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Other Assets Noncurrent | 8 | 8 | 7 | 7 | 7 | 4 | 3 | 2 | 2 | 2 | 4 | 4 | ||||||
| Assets | 752 | 648 | 751 | 262 | 324 | 384 | 436 | 503 | 342 | 177 | 203 | 218 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 23 | 28 | 20 | 22 | 23 | 5 | 5 | 3 | 3 | 6 | 3 | 3 | ||||||
| Accrued Liabilities Current | 65 | 44 | 32 | 27 | 26 | 21 | 20 | 18 | 12 | 7 | 9 | 4 | ||||||
| Employee Related Liabilities Current | 9 | 7 | 15 | 11 | 7 | 4 | 12 | 8 | 5 | 6 | 5 | 4 | ||||||
| Operating Lease Liability Current | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | ||||||
| Other Liabilities Current | 3 | 1 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 0 | ||||||
| Notes Payable Current | - | - | - | - | - | - | - | 25 | 100 | - | 0 | 100 | ||||||
| Liabilities Current | 104 | 83 | 73 | 65 | 60 | 35 | 42 | 59 | 140 | 23 | 20 | 114 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 17 | 17 | 18 | 3 | 2 | 3 | 3 | 4 | 5 | 6 | 3 | 4 | ||||||
| Other Liabilities Noncurrent | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 1 | ||||||
| Liabilities | 122 | 102 | 92 | 69 | 65 | 39 | 47 | 65 | 147 | 133 | 125 | 119 | ||||||
Stockholders Equity | ||||||||||||||||||
| Long Term Notes Payable | - | - | - | - | - | - | 0 | 0 | 0 | 100 | 100 | 0 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 8 | 8 | 8 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | ||||||
| Additional Paid In Capital | 3,324 | 3,024 | 2,948 | 2,263 | 2,098 | 1,617 | 1,598 | 1,586 | 1,287 | 1,076 | 1,066 | 1,051 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -3 | -3 | -3 | -3 | -3 | -3 | -2 | -2 | -2 | -2 | -2 | -2 | ||||||
| Retained Earnings Accumulated Deficit | -2,699 | -2,484 | -2,294 | -2,075 | -1,843 | -1,277 | -1,215 | -1,153 | -1,097 | -1,037 | -993 | -957 | ||||||
| Stockholders Equity | 630 | 546 | 659 | 192 | 259 | 344 | 389 | 438 | 195 | 44 | 78 | 99 | ||||||
| Liabilities And Stockholders Equity | 752 | 648 | 751 | 262 | 324 | 384 | 436 | 503 | 342 | 177 | 203 | 218 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | ||||||
| Common Stock Shares Issued | 793 | 776 | 775 | 744 | 743 | 742 | 738 | 737 | 724 | 702 | 702 | 698 | ||||||
| Shares Outstanding | 793 | 776 | 775 | 744 | 743 | 742 | 738 | 737 | 724 | 702 | 702 | 698 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialSummit Therapeutics Inc. (SMMT) — SEC Financial Statements & Analysis
Summit Therapeutics Inc. (SMMT) is a pharmaceutical preparations company. Summit Therapeutics Inc. trades on Nasdaq as: SMMT. Summit Therapeutics Inc. (SMMT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-23. Based on that filing, Summit Therapeutics Inc. carries a market cap of $11.34B, a P/E ratio of -13.24x, a P/B ratio of 18.00x, an enterprise value of $10.92B, and an EV/EBITDA multiple of -12.76x. On profitability, it posts a Return on Equity (ROE) of -192.50%, a Return on Assets (ROA) of -159.09%, and a Return on Invested Capital (ROIC) of -996.22%. Per share, it reports EPS of $-1.10, diluted EPS of $-1.10, free cash flow per share of $-0.59, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 14.75% year-over-year, and EPS growth of 9.50% year-over-year. On the balance sheet, it maintains a current ratio of 6.96x, a quick ratio of 6.67x, working capital of $617.01M, a debt-to-equity ratio of 0.19x, a debt ratio of 0.16, an interest coverage ratio of -102892.00x, free cash flow of $-459.82M (TTM), and net debt of $-419.68M. Figures sourced from SEC EDGAR.
- Market Cap
- $11.34B
- P/E TTM
- -13.24x
- EPS TTM
- $-1.10
- P/B TTM
- 18.00x
- ROE TTM
- -192.50%
- ROA TTM
- -159.09%
- Debt To Equity
- 0.19x
- Free Cash Flow TTM
- $-459.82M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Summit Therapeutics Inc. in?
Summit Therapeutics Inc. (SMMT) operates in the Pharmaceutical Preparations industry.
What exchange does SMMT trade on?
Summit Therapeutics Inc. (SMMT) trades on the Nasdaq.
When was Summit Therapeutics Inc. (SMMT)'s most recent SEC filing?
Summit Therapeutics Inc. (SMMT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-23.
What is SMMT's market cap?
Summit Therapeutics Inc. (SMMT) has a market capitalization of $11.34B as of 2026-06-30.
What is SMMT's EPS (earnings per share)?
Summit Therapeutics Inc. (SMMT)'s trailing twelve month EPS is $-1.10 as of 2026-06-30.
What is SMMT's ROE (return on equity)?
Summit Therapeutics Inc. (SMMT)'s trailing twelve month Return on Equity (ROE) is -192.50% as of 2026-06-30.
What is SMMT's ROA (return on assets)?
Summit Therapeutics Inc. (SMMT)'s trailing twelve month Return on Assets (ROA) is -159.09% as of 2026-06-30.
What is SMMT's ROIC (return on invested capital)?
Summit Therapeutics Inc. (SMMT)'s trailing twelve month Return on Invested Capital (ROIC) is -996.22% as of 2026-06-30.
What is SMMT's EV/EBITDA?
Summit Therapeutics Inc. (SMMT)'s trailing twelve month EV/EBITDA is -12.76x as of 2026-06-30.